Motion Media videophone used in Scottish TM project
Motion Media videophone used in Scottish TM projectMotion Media Technology, a developer of videotelephony products, is one of four companies in a consortium delivering home telecare services to elderly residents in West Lothian, Scotland, as
Motion Media videophone used in Scottish TM project
Motion Media Technology, a developer of videotelephony products, is one of four companies in a consortium delivering home telecare services to elderly residents in West Lothian, Scotland, as part of a US$1.5 million government-sponsored telemedicine project. The project, which is being managed by the West Lothian Council, is the largest of its kind in the U.K. Other participants include Turnstall Telecom, Possum Controls, and Technology in Healthcare.
In related news, Boston-based Motion Media is working with British Telecom to pilot its videophone technology for general home use by 120 families with young children. Each family is being lent up to three videophones to enable relatives living far away to visit regularly with the children.
- Search Again
- Return To HNN Homepage
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
